Navigation Links
KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM)

Potential NDA Approval for Gestiva(TM) Anticipated in Calendar 2008 Gestiva(TM), is Designated as an Orphan Drug by the FDA for the Prevention

of Preterm Birth in Singleton Pregnancies

ST. LOUIS, Jan. 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that it has entered into a definitive purchase agreement that gives KV full U.S. and worldwide rights to Gestiva(TM) (17-alpha hydroxyprogesterone caproate) upon approval of the pending Gestiva(TM) New Drug Application ("NDA").

The NDA for Gestiva(TM) is currently before the FDA, pending approval for use in the prevention of preterm birth in certain categories of pregnant women. The proposed indication is for to women with a history of at least one spontaneous preterm delivery (i.e., less than 37 weeks), who are pregnant with a single fetus. The FDA issued an "approvable" letter for Gestiva(TM) in October 2006, and a final approval is anticipated in late 2008. The FDA has granted an Orphan Drug Designation for Gestiva(TM).

KV is acquiring Gestiva(TM) from Massachusetts-based Hologic, Inc. for $82 million in cash, $7.5 million of which is payable at closing. The balance is payable upon final FDA approval and the production of launch quantities of Gestiva(TM). KV expects Gestiva(TM) to be additive to KV's earnings per share in the first 12 months following its launch.

"Gestiva(TM) marks an exciting and important extension to Ther-Rx's growing women's health franchise," said Marc S. Hermelin, Chairman of the Board and Chief Executive Officer of KV. "Our commitment to women's health is second-to-none in the industry and we believe the acquisition of Gestiva(TM), following the acquisition of our approved and soon-to-be-launched Evamist(TM) product and the continued growth of Ther-Rx's current women's health suite of products, charts a course for sustained growth and profitability for our branded business."

KV -- through its wholly-owned branded subsidiary, Ther-Rx Corporation -- has built an emerging leadership position in selected women's health therapies. Gestiva(TM) will join a product roster that includes:

-- PreCare(R), the best-selling line of branded prescription prenatal

vitamins which today have more than a 40% share of the branded

prescription prenatal market and include the leading brand in the

fast-growing Omega-3 segment of prescription prenatals -- PrimaCare(R)

-- and PrimaCare ONE(TM), which is the #1 individual product among all

prescription prenatals in the United States;

-- Leading one-dose prescription vaginal anti-infective products,

including Clindesse(R), the fastest growing branded intra-vaginal

prescription product for its labeled indication in the United States,

and Gynazole-1(R), the #1 branded cream product for its labeled

indication (based on prescriptions filled in the United States);

-- Leading products in the area of oral, prescription iron products, led

by the Company's unique Repliva 21/7(TM), the #1 branded oral

prescription hematinic product in the United States; and,

-- Evamist(TM), a novel new delivery dosage form and the first and only

FDA-approved transdermal estradiol spray, which is expected to be

launched early in calendar 2008, with estimated peak annual sales of

approximately $125 million.

The acquisition of Gestiva(TM) is intended to allow Ther-Rx to capitalize on the already strong relationships built over the past seven years between Ther-Rx's 300-member sales force and Obstetrician/Gynecologists. KV believes Gestiva(TM) is a perfect fit for Ther-Rx's sale force where it will be able to continue to expand its focus on women and their babies as a complement to Ther-Rx's leading selling line of branded prenatal vitamins.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate website at

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans," "expect," "aim," "believe," "projects," "anticipates," "commit," "intend," "estimate," "will," "should," "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, statements about the Company's strategy for growth, product development, product launches, regulatory approvals, market position, market share increases, acquisitions, revenues, expenditures and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (8) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive response to the Company's sales, marketing and strategic efforts; (13) risks that the Company may not ultimately prevail in litigation; (14) the proposed restatement of the Company's financial statements for fiscal periods from 1996 through 2006 and for the quarter ended June 30, 2006, as well as completion of the Company's financial statements for the second, third and fourth quarters of fiscal 2007 and for the full fiscal year ended March 31, 2007, and for the first, second and third quarter of fiscal 2008; (15) actions by the Securities and Exchange Commission and the Internal Revenue Service with respect to the Company's stock option grants and accounting practices; and (16) the risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission.

This discussion is by no means exhaustive, but is designed to highlight important factors that may impact the Company's outlook. We are under no obligation to update any of the forward-looking statements after the date of this release.

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
2. Pharmaceutical market fails pregnant women; and more
3. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
4. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
5. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
9. Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes
10. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
11. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
Post Your Comments:
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination of recycled ... way for homeless people to have a more dignified and comfortable night’s sleep. ... they are repurposing plastic bags into sleeping mats for the homeless. The ...
(Date:11/25/2015)... Mateo, CA (PRWEB) , ... November 25, 2015 , ... ... in prizes were awarded to winners of the Create Real Impact awards. California ... creative expression to help stem the tide of distracted and reckless driving, the number ...
(Date:11/24/2015)... GA (PRWEB) , ... November 24, 2015 , ... Dr. ... to now offer laser services to many of his patients. Dr. Afferica now uses ... designed to reduce the amount of time the doctor uses other traditional cutting tools, ...
(Date:11/24/2015)... SAN FRANCISCO, CA (PRWEB) , ... November 24, ... ... launched half-cup sizes, has launched their Black Friday sale a week early, offering ... ThirdLove continues to transform the intimate apparel industry through both mobile fit technology ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 /PRNewswire/ ... leader in non-invasive genetic testing and the ... that it will present at the 27 ... York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, ... Company,s financial results, business activities and financial ...
Breaking Medicine Technology: